Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events.
about
Learning Lessons from Adverse Drug Reactions in ChildrenBacterial meningitis in Malawian infants <2 months of age: etiology and susceptibility to World Health Organization first-line antibiotics.Evaluation of a potential clinical interaction between ceftriaxone and calciumSystematic review: neonatal meningitis in the developing world.Hypercalcemia in pregnancy: a case of milk-alkali syndrome.Development and evaluation of a test program for Y-site compatibility testing of total parenteral nutrition and intravenous drugsPharmacovigilance in children in Camagüey Province, CubaDextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: Implication of isoelectric precipitation of complement proteinsEarly-onset neonatal sepsis.Therapeutic management of bacterial meningitis in children: a systematic review and comparison of published guidelines from a European perspective.Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future.Otoacoustic emission screen results in critically ill neonates who received gentamicin in the first week of life.Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre.Adverse drug reactions in neonates: could we be documenting more?Late-onset sepsis in preterm infants: update on strategies for therapy and prevention.Adverse reaction to ceftriaxone in a 28-day-old infant undergoing urgent craniotomy due to epidural hematoma: review of neonatal biliary pseudolithiasis.Challenges Associated with Route of Administration in Neonatal Drug Delivery.Dynamic Image Analysis To Evaluate Subvisible Particles During Continuous Drug Infusion In a Neonatal Intensive Care Unit.Intravenous maintenance fluid therapy in children.Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature.The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants <60 days of Age in Malawi.Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents.Concomitant ceftriaxone and high-concentration intravenous calcium therapy in adult critical care patients: a matched cohort study.Ventricular access devices are safe and effective in the treatment of posthemorrhagic ventricular dilatation prior to shunt placement.Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model.Inappropriate medication administration practices in Canadian adult ICUs: a multicenter, cross-sectional observational study.Effectiveness of in-Line Filters to Completely Remove Particulate Contamination During a Pediatric Multidrug Infusion Protocol.
P2860
Q26740286-7355A3EF-E51D-49AE-B70C-B9A89FA64B6EQ33630042-A08ED76D-4474-450F-A68C-EAED2B510BF1Q33768920-5D21A839-9F38-4EB6-A85A-50127E8066CBQ34170056-82DC4336-627F-4856-AA53-B1F276FD6E3CQ35113176-E8CA031E-158E-4348-8E62-495C687B36CAQ35965129-431C1C00-A0EC-47D4-BCC8-D73362AB03A1Q36028529-5F6A66FA-2ED1-4FFE-BE69-A65C56B851BBQ37138219-ACAE388A-9046-417B-9E1D-E9C678CDC277Q37544901-2045A247-81DB-41A1-B6AF-D808D351C716Q37777886-0D5A6848-9171-467D-9A4E-1FB34ACBE887Q37872784-8E2A693D-6630-4C5C-A138-4908DA7C45E4Q37933379-E385009D-58FA-4913-B29F-6375E4FDE833Q37961946-4252713F-6F52-40E3-B924-6B96031D5138Q38250020-09EB01D3-B691-4B48-9046-939232CEB335Q38347714-DF47B428-4A4C-421E-81A4-C48D5EF2C92FQ38546483-BC829ED4-F2FE-42A2-95DC-5B1549F02740Q38561363-3FB1AEB3-8BC1-481B-8042-EE2A80D4229EQ38609383-BA7253DA-EFCF-49D6-9AB7-3078A06A25D7Q38803543-4AB9D9DF-7B20-4CF4-A8B8-1AFAAF378D11Q38975534-E19C979D-D5C5-48BD-8BBE-6B17FF772185Q39163753-C2D4E0B9-4D7F-4055-9C15-CE12C5506905Q39313622-48DC3746-8CEA-419A-AF48-12169504D922Q43041576-F138E7AE-42F1-4758-87C0-39AAACB290F1Q47341046-7ED1C279-9486-4979-BA30-8E1782E8B751Q47990056-59D17883-D3B7-4CB8-8D83-57A150D30BA4Q50190703-B536D023-A149-4C20-B9CE-6561D06BA589Q55023288-7A882B05-291B-470B-99DB-AB0E6C86E127
P2860
Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@ast
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@en
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@nl
type
label
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@ast
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@en
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@nl
prefLabel
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@ast
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@en
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@nl
P2093
P356
P1433
P1476
Intravenous ceftriaxone and ca ...... ardiopulmonary adverse events.
@en
P2093
John S Bradley
Ronald T Wassel
Sumathi Nambiar
P304
P356
10.1542/PEDS.2008-3080
P407
P577
2009-03-16T00:00:00Z